Skip to main content
Premium Trial:

Request an Annual Quote

NCI-Led Breast, Prostate Cancer Genotyping Study to Use ABI s Technology, Protocol

NEW YORK, April 18 (GenomeWeb News) - The National Cancer Institute's Cohort Consortium will use genotyping technology and protocols from Applied Biosystems to study the genetics of breast and prostate cancer, ABI said today.


The project, which combines six large prospective cohort studies that include more than 6,000 breast cancer and 8,000 prostate cancer patients, will make use of ABI's TaqMan SNP genotyping assays and 7,900HT real-time PCR systems to identify inherited gene variants that may contribute to the development of the two cancers. The SNP genotyping assays were designed by Applied Biosystems and will be made public to researchers.


Preliminary results from a first study by the Cohort Consortium started in 2003, entitled "Breast and Prostate Cancer and Hormone-Related Gene Variants Study," will be presented this week at the AACR meeting in Anaheim, Calif.


The NCI Cohort Consortium is a collaboration involving six American and European prospective cohort studies totaling 897,000 participants, three genomic facilities, and six genotyping centers.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more